Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1175286 | 1.00 | S1PR1 (0.80) | S1PR1S1PR3 | |
| SCHEMBL1174327 | 0.90 | S1PR1 (0.66) | S1PR1S1PR3 | |
| SCHEMBL1174331 | 0.90 | S1PR1 (0.66) | S1PR1S1PR3 | |
| SCHEMBL1174155 | 0.89 | S1PR1 (1.00) | S1PR1S1PR3 | |
| SCHEMBL1174152 | 0.89 | S1PR1 (1.00) | S1PR1S1PR3 | |
| SCHEMBL1174535 | 0.87 | S1PR1 (0.69) | S1PR1S1PR3 | |
| SCHEMBL1175096 | 0.84 | S1PR1 (0.91) | S1PR1S1PR3 | |
| SCHEMBL1175093 | 0.84 | S1PR1 (0.91) | S1PR1S1PR3 | |
| SCHEMBL1174283 | 0.83 | S1PR1 (0.90) | S1PR1S1PR3 | |
| SCHEMBL1174288 | 0.83 | S1PR1 (0.90) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410151-B2 | Aminomethyl benzene derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-02 | — | — | US | claimed |
| US-20110028449-A1 | NOVEL AMINOMETHYL BENZENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-03 | — | — | US | claimed |
| US-8410151-B2 | Aminomethyl benzene derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-02 | — | — | US | disclosed |
| EP-2262782-B1 | NOVEL AMINOMETHYL BENZENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-07-04 | — | — | EP | disclosed |
| US-20110028449-A1 | NOVEL AMINOMETHYL BENZENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-03 | — | — | US | disclosed |
| EP-2262782-A1 | NOVEL AMINOMETHYL BENZENE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009109904-A1 | NOVEL AMINOMETHYL BENZENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028449-A1 | NOVEL AMINOMETHYL BENZENE DERIVATIVES | CD47, BRD4, BRD3 | S1PR1 2558/4885S1PR3 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.